iSpecimen Inc (ISPC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
iSpecimen Inc stock (ISPC) is currently trading at $0.16. iSpecimen Inc PS ratio (Price-to-Sales) is 0.57. Analyst consensus price target for ISPC is $3.00. WallStSmart rates ISPC as Sell.
- ISPC PE ratio analysis and historical PE chart
- ISPC PS ratio (Price-to-Sales) history and trend
- ISPC intrinsic value — DCF, Graham Number, EPV models
- ISPC stock price prediction 2025 2026 2027 2028 2029 2030
- ISPC fair value vs current price
- ISPC insider transactions and insider buying
- Is ISPC undervalued or overvalued?
- iSpecimen Inc financial analysis — revenue, earnings, cash flow
- ISPC Piotroski F-Score and Altman Z-Score
- ISPC analyst price target and Smart Rating
iSpecimen Inc
📊 No data available
Try selecting a different time range
Smart Analysis
iSpecimen Inc (ISPC) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
iSpecimen Inc (ISPC) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
iSpecimen Inc (ISPC) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -96.00%, a shrinking business
Very low institutional interest at 1.30%
Micro-cap company with very limited liquidity and high volatility
iSpecimen Inc (ISPC) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book. Valuation metrics including Price/Sales (0.57), Price/Book (0.58) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -96.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -296.20%, Operating Margin at -2655.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -296.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -96.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ISPC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ISPC's Price-to-Sales ratio of 0.57x trades at a deep discount to its historical average of 2.27x (22th percentile). The current valuation is 97% below its historical high of 20.91x set in Nov 2021, and 148% above its historical low of 0.23x in Mar 2024. Over the past 12 months, the PS ratio has compressed from ~1.2x as trailing revenue scaled faster than the stock price.
Compare ISPC with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for iSpecimen Inc (ISPC) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
iSpecimen Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 3M with 96% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.09 indicates a conservative balance sheet with 3M in cash.
Spending 16% of revenue (551,104) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 96% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.88, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact iSpecimen Inc.
Bottom Line
iSpecimen Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About iSpecimen Inc(ISPC)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
iSpecimen, Inc. provides technology that connects life science researchers in need of human biofluids, tissues and living cells for their research with biospecimens available from healthcare provider organizations globally. The company is headquartered in Lexington, Massachusetts.